RxDoctor Payments Data

Sandhya Iyer, MD

Ophthalmology · Fort Worth, TXNPI 1285708073

Payments from drug & device makers

$2,044in general payments, 2019–2025

Across 48 payments — averaging $42.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$330
  • Sun Pharmaceutical Industries Inc.$243
  • Tarsus Pharmaceuticals, Inc.$224
  • Alcon$207
  • Bausch & Lomb Americas Inc.$162
  • Coopervision Inc.$131
  • plus $747 from 11 others

What the payments were for

  • Food & beverage$2,044100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,044 in reported general payments places this provider in the 50th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$250,126
Medicare patients
680
Services billed
1,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine99$72,554
Prednisolone Acetate737$24,427
ProlensaBromfenac Sodium37$14,029
MoxifloxacinMoxifloxacin Hcl462$12,552
XiidraLifitegrast13$9,819
Cyclosporine30$8,834
ValacyclovirValacyclovir Hcl183$6,466
LumiganBimatoprost18$4,566
Latanoprost299$2,287
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat110$1,927
Difluprednate19$1,300
Fluorometholone17$1,100
Timolol Maleate71$823
ErythromycinErythromycin Base35$392
Acyclovir19$326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$55$77,120117 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$118$14,02937 claims
Bausch & Lomb Americas Inc.Xiidra$162$9,81913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →